Implications of serum basic fibroblast growth factor levels in chronic liver diseases and hepatocellular carcinoma

Ping I. Hsu, Nan Haw Chow, Kwok Hung Lai, Hsiao Bai Yang, Shih Huang Chan, X. I.Zhang Lin, Jin Shiung Cheng, Jia Sheng Huang, Luo Ping Ger, Shih Min Huang, Muh Yong Yen, Yun Fu Yang

研究成果: Article同行評審

41 引文 斯高帕斯(Scopus)

摘要

Angiogenesis occurs in response to tissue damage, and is of vital importance for tumor growth and metastasis. Basic fibroblast growth factor (bFGF), a well-known angiogenic factor, has been suggested to be a useful diagnostic marker in certain hypervascular tumors. However, the relevance of its detection has not been well evaluated in patients with hepatocelluar carcinoma (HCC) and benign chronic liver diseases. In the current study, immunoassay of bFGF was performed on serum samples from 39 patients with HCC, 21 with liver cirrhosis, 22 with chronic hepatitis and 40 normal subjects. The serum bFGF level was significantly increased in patients with liver cirrhosis and HCC when compared with those with chronic hepatitis or normal subjects (all p-values < 0.001). However, no difference was observed between the groups with liver cirrhosis and HCC (p > 0.05). If we set 9.6 pg/ml (mean + 3 standard deviations of bFGF in the control group) as the upper limit of normal serum level of bFGF, elevated bFGF concentrations were noted in 9.1%, 42.9% and 51.3% of patients with chronic hepatitis, liver cirrhosis and HCC respectively. In non-cancer patients the coexistence of acute illness (p = 0.000) was an independent factor related to the elevation of serum bFGF. On the other hand, a multivariate analysis demonstrated that both advanced stage of cancer (p = 0.026) and coexistence of acute illness (p = 0.000) influence the serum level of bFGF in patients with HCC. We conclude that serum bFGF levels are significantly higher in patients with HCC and are positively correlated with advanced tumor stage. Nevertheless, elevation of serum bFGF may also be observed in a significant number of patients with liver cirrhosis. Therefore, measurement of serum bFGF alone cannot be satisfactory as a tumor marker for diagnosis of HCC. In addition, it is important to point out that coexistence of acute illness may be a crucial confounding factor in the diagnosis or monitoring of any cancer by the estimation of selum bFGF.

原文English
頁(從 - 到)2803-2809
頁數7
期刊Anticancer research
17
發行號4 A
出版狀態Published - 1997

All Science Journal Classification (ASJC) codes

  • 腫瘤科
  • 癌症研究

指紋

深入研究「Implications of serum basic fibroblast growth factor levels in chronic liver diseases and hepatocellular carcinoma」主題。共同形成了獨特的指紋。

引用此